Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 61Neoplasm Metastasis 6Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Melanoma 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Meningioma 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFR-mutant Non-small Cell Lung Cancer × ribociclib × 1 year × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡